Middle East & Africa Cell And Gene Therapy Clinical Trials Market Size & Outlook

The cell and gene therapy clinical trials market in Middle East & Africa is expected to reach a projected revenue of US$ 510.8 million by 2030. A compound annual growth rate of 8.1% is expected of Middle East & Africa cell and gene therapy clinical trials market from 2024 to 2030.
Revenue, 2023 (US$M)
$295.9
Forecast, 2030 (US$M)
$510.8
CAGR, 2024 - 2030
8.1%
Report Coverage
Middle East & Africa

Middle East & Africa cell and gene therapy clinical trials market, 2018-2030 (US$M)

Middle

MEA cell and gene therapy clinical trials market highlights

  • The MEA cell and gene therapy clinical trials market generated a revenue of USD 295.9 million in 2023.
  • The market is expected to grow at a CAGR of 8.1% from 2024 to 2030.
  • In terms of segment, phase ii was the largest revenue generating phase in 2023.
  • Phase II is the most lucrative phase segment registering the fastest growth during the forecast period.
  • Country-wise, South Africa is expected to register the highest CAGR from 2024 to 2030.


MEA data book summary

Market revenue in 2023USD 295.9 million
Market revenue in 2030USD 510.8 million
Growth rate8.1% (CAGR from 2023 to 2030)
Largest segmentPhase ii
Fastest growing segmentPhase II
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPhase I, Phase II, Phase III, Phase IV
Key market players worldwideIQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech


Other key industry trends

  • In terms of revenue, MEA region accounted for 3.2% of the global cell and gene therapy clinical trials market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 4,499.3 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cell And Gene Therapy Clinical Trials Market Companies

Name Profile # Employees HQ Website

Middle East & Africa cell and gene therapy clinical trials market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.


Phase ii was the largest segment with a revenue share of 52.38% in 2023. Horizon Databook has segmented the Middle East & Africa cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.


Conducting cell and gene therapy clinical trials in MEA offers advantages such as patient diversity; cost advantage, infrastructure, and world-class medical facilities. The only drawback is discrepancies between laws of different regions. Many regions are initiating to adapt to the global standards and collaborating with other global CROs to mark their presence.

For instance, Hassan Labs of Egypt and Saham Group of North Africa joined hands to provide international level of medical expertise across Africa. Many countries are implementing global standards and collaborating with other global CROs to mark their presence.

For instance, in September 2020, CTI Clinical Trial and Consulting Services acquired Clinart to expand its presence in the MEA region. Outsourcing clinical trials to a local CRO in the region with regional language proficiency, local regulatory expertise, patient recruitment & site management would be beneficial for companies trying to gain higher shares in the MEA market.

Reasons to subscribe to Middle East & Africa cell and gene therapy clinical trials market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Middle East & Africa cell and gene therapy clinical trials market databook

  • Our clientele includes a mix of cell and gene therapy clinical trials market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa cell and gene therapy clinical trials market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

MEA cell and gene therapy clinical trials market size, by country, 2018-2030 (US$M)

Middle East & Africa Cell And Gene Therapy Clinical Trials Market Outlook Share, 2023 & 2030 (US$M)

MEA cell and gene therapy clinical trials market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more